Nisa Investment Advisors’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Nisa Investment Advisors’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-16,140	Closed	-$775K	–	2150
2020 Q1	$775K	Buy	16,140 +340	+2%	+$15.8K	0.01%	779
2019 Q4	$741K	Hold	15,800	–	–	0.01%	984
2019 Q3	$374K	Hold	15,800	–	–	﹤0.01%	1175
2019 Q2	$475K	Hold	15,800	–	–	﹤0.01%	1087
2019 Q1	$354K	Hold	15,800	–	–	﹤0.01%	1158
2018 Q4	$288K	Hold	15,800	–	–	﹤0.01%	1146
2018 Q3	$286K	Hold	15,800	–	–	﹤0.01%	1238
2018 Q2	$157K	Buy	+15,800	New	+$109K	﹤0.01%	1300

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Nisa Investment Advisors's RARX Position: Q2 2020 in Review

Nisa Investment Advisors sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 16,140 shares — an estimated $775K sold.

Nisa Investment Advisors first reported a position in RARX in Q2 2018 and held it in 8 quarters. The position peaked at $775K in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Nisa Investment Advisors reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Nisa Investment Advisors sold 16,140 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $775K.
Nisa Investment Advisors first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
Nisa Investment Advisors's Ra Pharmaceuticals, Inc. Common Stock position peaked at $775K in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Nisa Investment Advisors's 13F filing for Q2 2020, filed 27 Jul 2020.